Advertisement

Analysis of Ribociclib Finds it is Not Cost-Effective Despite Significant Survival Benefit

Ribociclib is approved for use in combination with an aromatase inhibitor for the first-line treatment of pre- and perimenopausal women with hormone receptor-positive, human...

Cost Comparison of Two Influenza Vaccines for Older Adults

Adjuvanted trivalent influenza vaccine (aTIV) and trivalent high dose influenza vaccine (TIV-HD) have shown different clinical benefits, so researchers assessed the annualized mean all-cause...

Health Policy Changes on the Horizon in an Election Year

A variety of health policy proposals have been rolled out in the face of an election year where health care is a top...

How to Manage High-Cost Gene and Cell Therapies

Gene and cell therapies are high-cost drugs that are increasingly becoming burdensome to the health care system. During a presentation at AMCP eLearning Days,...
Advertisement